Alnylam Pharmaceuticals ALNY Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alnylam Pharmaceuticals's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alnylam Pharmaceuticals's financing cash flow?
- Alnylam Pharmaceuticals (ALNY) reported financing cash flow of $36.24M in Q2 2026.
- How has Alnylam Pharmaceuticals's financing cash flow changed year-over-year?
- Alnylam Pharmaceuticals's financing cash flow decreased by 32.6% year-over-year, from $53.76M to $36.24M.
- What is the long-term trend for Alnylam Pharmaceuticals's financing cash flow?
- Over 3 years (2021 to 2024), Alnylam Pharmaceuticals's financing cash flow has grown at a -38.2% compound annual growth rate (CAGR), from $1.25B to $294.16M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.